Article Information
History
- March 13, 2024.
Article Versions
- Version 1 (January 23, 2024 - 21:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Dorothée Diogo1,*,
- Emily H.M. Wong2,8,
- Christopher DeBoever2,
- Wei Qu3,
- Jonghun Lee1,
- Stephen Crawford4,
- Takeshi Hioki5,
- Jaya Padmanabhan6,
- Daria Prilutsky1 and
- Gabriele Proetzel7
- 1Genetics and Systems Biology, Takeda Development Center Americas, Inc., Cambridge, MA 02139
- 2Genetics and Systems Biology, Takeda Development Center Americas, Inc., San Diego, CA 92121
- 3Genetics and Systems Biology, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
- 4Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Cambridge, MA 02142
- 5Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
- 6Neuroscience Therapeutic Area Unit, Takeda Development Center Americas, Inc., Cambridge, MA 02142
- 7Neuroscience Drug Discovery Unit, Takeda Development Center Americas, Inc., Cambridge, MA 02142
- 8Current address: Data Science and Operations, Vir Biotechnology Inc., San Francisco, CA 94158
- ↵*Corresponding author: Dorothée Diogo 35 Lansdowne street, Cambridge, MA 02139, USA dorothee.diogo{at}takeda.com
Posted March 13, 2024.
Estimated genetics prevalence of early-onset Parkinson’s disease caused by PRKN mutations
